Adjuvant treatment in operable breast cancer

A. Goldhirsch

Research output: Contribution to journalArticlepeer-review


The object of Ludwig III was to assess adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastases. Chemo-endocrine therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone and tamoxifen: CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen: p + T) and with no adjuvant treatment in 463 evaluable patients aged 65 years or less. Treatment results are available (Ludwig Breast Cancer Study Group, Lancet i (1984) 1256-1260). Nodal status and receptor content of the primary were found to have prognostic value, while tumor size did not.

Original languageEnglish
Pages (from-to)1155-1160
Number of pages6
JournalJournal of Steroid Biochemistry
Issue number6 PART 2
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology


Dive into the research topics of 'Adjuvant treatment in operable breast cancer'. Together they form a unique fingerprint.

Cite this